Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro:: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3

被引：0

|

作者：

Mink, M

Greenberg, M

Moiser, S

Janumpalli, S

Davison, D

Jin, L

Melby, T

Sista, P

Lambert, D

Cammack, N

Salgo, M

Matthews, T

机构：

[1] Trimeris Inc, Durham, NC USA

[2] Roche Biosci, Palo Alto, CA USA

[3] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

来源：

ANTIVIRAL THERAPY | 2002年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

22

引用

收藏

页码：S24 / S24

页数：1

相关论文

共 2 条

[1] Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in Phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates
Sista, P
Melby, T
Greenberg, ML
Davison, D
Jin, L
Moiser, S
Mink, M
Nelson, E
Fang, L
Cammack, N
Salgo, M
Matthews, TJ
ANTIVIRAL THERAPY, 2002, 7 : S23 - S23
[2] Substitutions within HIV gp41 amino acids 36-45 are identified as the primary determinants for loss of in vitro susceptibility to enfuvirtide:: results of data mining analyses of genotypic changes in gp41 in TORO 1 and TORO 2 that associate with changes in phenotypic susceptibility to enfuvirtide
Su, C
Heilek-Snyder, G
Ravindran, P
Melby, T
Chiu, S
Cammack, N
ANTIVIRAL THERAPY, 2004, 9 (04) : U120 - U121